Raise closed, search for fresh raises on Seedstage

Austin, TX

Developing a novel treatment to prevent opioid dependence and improve pain management.

• Mission: Addressing the opioid crisis by developing Low Dose 6β-Naltrexol (ATX-001), a novel treatment aimed at preventing opioid dependence while maintaining effective pain relief.  
• Innovation: Offering a groundbreaking approach to pain management and addiction prevention, with preclinical studies showing promise in preventing dependence without withdrawal symptoms.  
• Healthcare Impact: Targeting non-addictive pain therapy, supporting drug rehabilitation, and preventing Neonatal Opioid Withdrawal Syndrome (NOWS), aiming to reduce the societal burden of opioid addiction.  
• Funding Uses: Securing capital for regulatory submissions, clinical trials, and advancing key milestones in the development of ATX-001.  
• Research Foundation: Backed by significant non-dilutive funding from the NIH, æther THERAPEUTICS is poised to make a transformative impact on opioid addiction treatment.  
• Leadership: Led by a team of experts in drug development, molecular biology, and pharmacology, committed to creating innovative therapies that address both the symptoms and causes of opioid dependence.  

æther THERAPEUTICS is dedicated to addressing the opioid crisis through the development of Low Dose 6β-Naltrexol (ATX-001), a novel treatment aimed at preventing opioid dependence while maintaining effective pain relief.

The company envisions a future where the adverse effects of opioid addiction are significantly reduced, allowing for safer pain management and the potential reversal of opioid addiction. ATX-001 has shown promise in preclinical studies, demonstrating the ability to prevent dependence and hyperalgesia without inducing withdrawal symptoms.

This innovative approach targets three key therapeutic areas: non-addictive pain therapy, support for patients in drug rehabilitation programs, and prevention of Neonatal Opioid Withdrawal Syndrome (NOWS).

With a strong foundation of research and funding, including significant non-dilutive support from the NIH, æther THERAPEUTICS is poised to advance its mission of alleviating the societal impact of opioid addiction.

The current fundraising effort aims to secure additional capital to facilitate upcoming milestones, including regulatory submissions and clinical trials, ultimately contributing to a world free from the devastating effects of opioid addiction.

Company Info

Aether Therapeutics develops treatments for opioid-related conditions, focusing on Neonatal Abstinence Syndrome.

Aether Therapeutics is a biopharmaceutical company based in Austin that focuses on developing innovative treatments for conditions related to the opioid epidemic, particularly Neonatal Abstinence Syndrome (NAS). The company has received significant funding, including a $1.7 million SBIR Fast-Track Grant, to support its research and development efforts. Aether is collaborating with various neonatal research centers in Ohio to improve care protocols for infants affected by opioid exposure. Their primary product, Low Dose 6 Beta Naltrexol (LD-6BN), is being studied for its potential to modulate opioid dependence and improve pain management, addressing the challenges of opioid addiction and withdrawal. Aether’s team comprises experts in drug development, molecular biology, and pharmacology, who aim to create effective therapies that not only treat symptoms but also target the underlying causes of addiction and dependence.